Anti-Retroviral Drugs
key details
| Status | complete |
|---|---|
| Category (CPV) | 33600000 |
| Region | Wales |
| Deadline | 18 Aug 2021 |
| Procedure | open |
| OCID | ocds-h6vhtk-02c9cb |
Awards (12)
This procurement was awarded to 12 suppliers. Values shown are per-award; the notice total is ·.
| Supplier | Value | Date | Status |
|---|---|---|---|
| Accord-UK Ltd shared | · | · | active |
| Aurobindo (Milpharm Ltd) shared | · | · | active |
| Bristol-Myers Squibb Pharmaceuticals Ltd shared | · | · | active |
| Dr Reddy’s Laboratories (UK) Ltd shared | · | · | active |
| Gilead Sciences Limited shared | · | · | active |
| Glenmark Pharmaceuticals shared | · | · | active |
| Janssen Limited shared | · | · | active |
| Merck Sharp & Dohme (UK) Limited shared | · | · | active |
| Ranbaxy UK Limited (Sun Pharma) shared | · | · | active |
| Tillomed Laboratories Ltd shared | · | · | active |
| Viatris UK Healthcare Ltd shared | · | · | active |
| ViiV Healthcare shared | · | · | active |
description
Anti-Retroviral Drugs
notice history
2 notices published against this procurement.
| Published | Type | Regime | Notice |
|---|---|---|---|
| 19 Jul 2021 | Contract notice (F02) | Earlier regulations | 016990-2021 |
| 14 Jan 2022 | Contract award notice (F03) | Earlier regulations | 001261-2022 |
more from Velindre NHS Trust, NHS Wales Shared Services Partnership - Procurement Services (on behalf of All Wales LHB's and Trusts)
- Unlicensed Medicines - Imports & Specials · 20 Jan 2025
- Aseptically Prepared Systemic Anti-Cancer Treatment (SACT) · 9 Aug 2024
- Generic Anti-Infective Drugs · £3,390,876 · 19 Mar 2024
- Licensed Bulk Medicines · £42,317,737 · 9 Jun 2023
- Lenalidomide · 9 Dec 2022
- Transitional Drugs · 11 Oct 2022
- Generic Drugs - Injections/Infusions · 3 Aug 2022
- Proprietary Drugs · 14 Jul 2022
all contracts from this buyer →
similar contracts awarded
Other awarded contracts in the same category. Useful for seeing who normally wins this kind of work, and at what value.
- Radiopharmaceutical Products - Poltech · The Christie NHS Foundation Trust · £39,000
- NHS Branded Medicines - Tranche B - London & South of England - 1 September 2026 · NHS England · £592,363,416
- NHS National Generics Pharmaceuticals - Supply Chain Resilience · NHS England · £52,447,296
- Generic, Branded Generic & Proprietary Medicinal Products - Group 18 · Regional Business Services Organisation, Procurement and Logistics Service · £1,800,000,000
- Generic Drugs – Injections/Infusions 2 · NHS Wales Shared Services Partnership-Procurement Services (hosted by Velindre University NHS Trust) · £6,535,850
- Transitional Drugs 7 · NHS Wales Shared Services Partnership-Procurement Services (hosted by Velindre University NHS Trust) · £53,566,932
- NP90726m Vedolizumab (Entyvio®) · The Common Services Agency (more commonly known as Public Services Delivery Scotland) (PSD Scotland) · £47,898,609
- Combined Needles and Syringes Lot 1 · Secretary of State for Health and Social Care acting as part of the Crown through UK Health Security Agency · £15,264,000
source
Published on Find a Tender. Contact details for named individuals are not reproduced on this site.